I P Romanov, T A Bogush, A M Scherbakov, A N Grishanina, E A Bogush, A B Ravcheeva, V S Kosorukov
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Gause Institute of New Antibiotics, Moscow, Russia.
Ir J Med Sci. 2025 Mar 21. doi: 10.1007/s11845-025-03917-4.
Progesterone receptors (PRs) play a role in the regulation of cell proliferation and are expressed in non-small cell lung cancer (NSCLC) tissue. Therefore, they represent a potential target for novel antitumor therapies. A survival analysis of NSCLC patients based on PR expression in tumor tissue may help assess the feasibility of using PR modulators in the treatment of this disease.
This study aims to evaluate the prognostic significance of PR expression in NSCLC to determine the potential utility of PR modulators as a therapeutic strategy.
PR expression was assessed in 130 surgically resected NSCLC samples using immunofluorescence analysis combined with flow cytometry. Primary antibodies against PR (NBP2-4638, Novus Biologicals, USA) and secondary antibodies conjugated with DyLight650 (ab98729, Abcam, UK) were used. The percentage of PR-expressing cells was quantified using FlowJo software. Statistical analyses were conducted in GraphPad Prism and RStudio using the "survival" package. The prognostic impact of PR expression in NSCLC tissue was evaluated in the overall patient cohort and after excluding censored events (n = 56) to minimize the influence of confounding factors on survival analysis.
After excluding censored events and stratifying patients based on the median PR expression level (57%), survival analysis revealed that high PR expression in NSCLC tissue is associated with a poorer prognosis (p = 0.05). Patients with high PR expression (≥ 57%) had a median survival of 12.8 months, whereas those with low PR expression (< 57%) had a median survival of 25.8 months (HR = 1.7).
Elevated PR expression in NSCLC tumors is associated with reduced patient survival. These findings suggest that PR modulators may have potential therapeutic value for NSCLC patients with PR-positive tumors.
孕激素受体（PRs）在细胞增殖调控中发挥作用，且在非小细胞肺癌（NSCLC）组织中表达。因此，它们是新型抗肿瘤治疗的潜在靶点。基于肿瘤组织中PR表达对NSCLC患者进行生存分析，可能有助于评估使用PR调节剂治疗该疾病的可行性。
本研究旨在评估PR表达在NSCLC中的预后意义，以确定PR调节剂作为一种治疗策略的潜在效用。
采用免疫荧光分析结合流式细胞术，对130例手术切除的NSCLC样本中的PR表达进行评估。使用抗PR的一抗（NBP2 - 4638，美国Novus Biologicals公司）和与DyLight650偶联的二抗（ab98729，英国Abcam公司）。使用FlowJo软件对表达PR的细胞百分比进行定量。使用“生存”软件包在GraphPad Prism和RStudio中进行统计分析。在整个患者队列中以及排除截尾事件（n = 56）后，评估NSCLC组织中PR表达的预后影响，以尽量减少混杂因素对生存分析的影响。
排除截尾事件并根据PR表达水平中位数（57%）对患者进行分层后，生存分析显示NSCLC组织中PR高表达与较差的预后相关（p = 0.05）。PR高表达（≥57%）的患者中位生存期为12.8个月，而PR低表达（<57%）的患者中位生存期为25.8个月（HR = 1.7）。
NSCLC肿瘤中PR表达升高与患者生存率降低相关。这些发现表明，PR调节剂可能对PR阳性肿瘤的NSCLC患者具有潜在治疗价值。
